文献速递药物不良反应与药物警戒

大型上市后心血管代谢试验对欧盟药品标签安全性更新的影响

Safety-Related Drug Label Changes Following Large Post-Marketing Cardiometabolic Trials: A Review of European Public Assessment Reports.
PubMed 文献 · Clin Pharmacol Ther · 2023-01-18

该综述评估2000–2020年获批的心血管代谢药物在初始授权后,基于大型临床试验(>1000例)提交至欧洲药品管理局(EMA)的数据对药品标签「不良反应」部分的更新情况。EMA共审查25个药物的55项大型试验、402,444例患者,38项试验(69%)导致安全性部分更新,19项试验(35%)涉及12个药物不良反应条目变化,新增77项、删除11项、43项频率改变。

要点

  • 大型上市后试验中69%导致安全性部分更新,但仅35%改变不良反应条目。
  • 不良反应变化多来自抗血栓药物试验(88%)和新人群试验(92%)。
  • 在已充分研究人群中开展的大型试验新增安全性信息有限。

核心结论

  • 心血管代谢药物授权后大型试验增加的不良反应安全性信息有限,尤其在获批前已研究人群中开展的试验。

研究设计与样本

  • 综述性评估,分析2000–2020年获批的心血管代谢药物(降糖、抗血栓、调脂)在初始授权后提交EMA的大型临床试验(>1000例)对药品标签「不良反应」部分的更改。
  • EMA审查了25个药物的55项大型试验,共纳入402,444例患者。

主要发现

  • 38项试验(69%)导致安全性部分更新,17项试验(31%)未导致更新。
  • 19项试验(35%)涉及12个药物的不良反应条目变化:新增77项不良反应、删除11项、43项频率改变。
  • 大多数不良反应变化来自抗血栓药物试验(88%)和新人群试验(92%)。

临床怎么用

  • 提示选择性安全性数据收集不减少在既往充分研究人群中开展的心血管代谢晚期试验的安全性学习价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selective safety data collection may simplify late-stage clinical trials and improve their feasibility. However, the impact on increasing overall drug safety knowledge is unknown. The aim of this study is to evaluate how much safety information is added to the drug label based on large trials after initial authorization. Changes made to the "undesirable effects" section of the drug label of cardiometabolic agents approved between 2000 and 2020 based on the results of large (> 1,000 patient) clinical trials submitted to the European Medicines Agency (EMA) were evaluated. The study focused on glucose lowering, antithrombotic, and lipid-modifying agents. The primary outcome was the number of changes in adverse drug reactions in the drug label. The EMA reviewed 55 large trials concerning 25 cardiometabolic agents after the initial marketing authorization, which included 402,444 patients. Ultimately, 38 trials (69%) resulted in a safety section update, whereas 17 trials (31%) did not. Changes in listed adverse drug reactions were made following 19 trials (35%) for 12 agents: 77 adverse drug reactions were added, 11 were deleted, and the frequencies of 43 were changed. Most changes in adverse drug reactions arose from trials with antithrombotic agents (88%) and trials performed in a new population (92%). Large trials for cardiometabolic agents reported after authorization add limited new safety information on adverse drug reactions, especially when performed in the population studied prior to approval. This suggests that selective safety data collection does not reduce learnings from late stage cardiometabolic trials in populations comprehensively studied before.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Starokozhko V, Tarrahi F, Vrijlandt PJWS, et al. Safety-Related Drug Label Changes Following Large Post-Marketing Cardiometabolic Trials: A Review of European Public Assessment Reports. Clin Pharmacol Ther. 2023. PMID: 36606727. doi:10.1002/cpt.2840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。